Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study.
Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study.
复制标题
DOI：
10.1016/j.eclinm.2023.101896
复制
发表时间：
2023-03
影响因子：
15.1
通讯作者：
HOSP-COVID Study Collaborat Grp
中科院分区：
文献类型：
--
作者：
McAuley, Hamish J. C.;Evans, Rachael A.;Bolton, Charlotte E.;Brightling, Christopher E.;Chalmers, James D.;Docherty, Annemarie B.;Elneima, Omer;Greenhaff, Paul L.;Gupta, Ayushman;Harris, Victoria C.;Harrison, Ewen M.;Ho, Ling-Pei;Horsley, Alex;Houchen-Wolloff, Linzy;Jolley, Caroline J.;Leavy, Olivia C.;Lone, Nazir I.;Man, William D. C.;Marks, Michael;Parekh, Dhruv;Poinasamy, Krisnah;Quint, Jennifer K.;Raman, Betty;Richardson, Matthew;Saunders, Ruth M.;Sereno, Marco;Shikotra, Aarti;Singapuri, Amisha;Singh, Sally J.;Steiner, Michael;Tan, Ai Lyn;Wain, Louise, V;Welch, Carly;Whitney, Julie;Witham, Miles D.;Lord, Janet;Greening, Neil J.;HOSP-COVID Study Collaborat Grp
COVID-19的规模及其有据可查的长期后遗症支持了解包括虚弱在内的长期结果的必要性。这项前瞻性队列研究招募了英国35个研究中心（PHOSP-COVID）中临床诊断为COVID-19的住院幸存成年人。使用Fried虚弱表型（FFP）客观地测量虚弱负担。主要结局是出院后5个月和1年时每个FFP组的患病率-强健（无FFP标准），虚弱前（1或2个FFP标准）和虚弱（3个或更多FFP标准）。为了纳入主要分析，参与者需要五个FFP标准中的三个的完整结果数据。在住院后5个月和1年报告了虚弱领域的纵向变化，沿着虚弱状态的风险因素。回顾性评估了COVID-19前的患者感知恢复和健康相关生活质量（HRQoL），并在5个月和1年访视时进行了前瞻性评估。本研究在ISRCTN注册，编号ISRCTN 10980107。在2020年3月5日至2021年3月31日期间，2419名参与者入组了FFP数据。平均年龄为57.9岁（SD 12.6），933例（38.6%）为女性，429例（17.7%）接受过有创机械通气。1785例患者在两个时间点进行了测量，其中5个月时分别有240例（13.4%）、1138例（63.8%）和407例（22.8%）为虚弱、虚弱前期和强健，而1年时分别有123例（6.9%）、1046例（58.6%）和616例（34.5%）。与虚弱前期或虚弱相关的因素是有创机械通气、年龄较大、女性和更大的社会剥夺。与COVID-19患病前相比，虚弱参与者的HRQoL下降幅度更大，并且不太可能将自己描述为康复。因COVID-19住院后，身体虚弱和虚弱前期很常见。在5到12个月之间，虚弱程度有所改善，尽管三分之二的人仍然处于虚弱前或虚弱状态。这表明，需要针对虚弱前和虚弱期以外的初始疾病进行全面评估和干预。 和.
The scale of COVID-19 and its well documented long-term sequelae support a need to understand long-term outcomes including frailty. This prospective cohort study recruited adults who had survived hospitalisation with clinically diagnosed COVID-19 across 35 sites in the UK (PHOSP-COVID). The burden of frailty was objectively measured using Fried's Frailty Phenotype (FFP). The primary outcome was the prevalence of each FFP group—robust (no FFP criteria), pre-frail (one or two FFP criteria) and frail (three or more FFP criteria)—at 5 months and 1 year after discharge from hospital. For inclusion in the primary analysis, participants required complete outcome data for three of the five FFP criteria. Longitudinal changes across frailty domains are reported at 5 months and 1 year post-hospitalisation, along with risk factors for frailty status. Patient-perceived recovery and health-related quality of life (HRQoL) were retrospectively rated for pre-COVID-19 and prospectively rated at the 5 month and 1 year visits. This study is registered with ISRCTN, number ISRCTN10980107. Between March 5, 2020, and March 31, 2021, 2419 participants were enrolled with FFP data. Mean age was 57.9 (SD 12.6) years, 933 (38.6%) were female, and 429 (17.7%) had received invasive mechanical ventilation. 1785 had measures at both timepoints, of which 240 (13.4%), 1138 (63.8%) and 407 (22.8%) were frail, pre-frail and robust, respectively, at 5 months compared with 123 (6.9%), 1046 (58.6%) and 616 (34.5%) at 1 year. Factors associated with pre-frailty or frailty were invasive mechanical ventilation, older age, female sex, and greater social deprivation. Frail participants had a larger reduction in HRQoL compared with before their COVID-19 illness and were less likely to describe themselves as recovered. Physical frailty and pre-frailty are common following hospitalisation with COVID-19. Improvement in frailty was seen between 5 and 12 months although two-thirds of the population remained pre-frail or frail. This suggests comprehensive assessment and interventions targeting pre-frailty and frailty beyond the initial illness are required. and .
登录
查看更多内容
影响因子：
76.2
作者：
Evans, Rachael A.;Leavy, Olivia C.;Richardson, Matthew;Elneima, Omer;McAuley, Hamish J. C.;Shikotra, Aarti;Singapuri, Amisha;Sereno, Marco;Saunders, Ruth M.;Harris, Victoria C.;Aul, Raminder;Beirne, Paul;Bolton, Charlotte E.;Brown, Jeremy S.;Choudhury, Gourab;Bakerly, Nawar Diar;Easom, Nicholas;Echevarria, Carlos;Fuld, Jonathan;Hart, Nick;Hurst, John R.;Jones, Mark;Parekh, Dhruv;Pfeffer, Paul;Rahman, Najib M.;Rowland-Jones, Sarah;Shah, Ajay M.;Wootton, Dan G.;Chalder, Trudie;Davies, Melanie J.;De Soyza, Anthony;Greenhalf, William;Greening, Neil J.;Heaney, Liam G.;Heller, Simon;Howard, Luke;Jacob, Joseph;Jenkins, R. Gisli;Lord, Janet M.;Man, Will D-C;McCann, Gerry P.;Neubauer, Stefan;Openshaw, Peter J. M.;Porter, Joanna;Quint, Jennifer;Rowland, Matthew J.;Scott, Janet T.;Semple, Malcolm G.;Singh, Sally J.;Toshner, Mark;Lewis, Keir;Briggs, Andrew;Docherty, Annemarie B.;Kerr, Steven;Lone, Nazir, I;Sheikh, Aziz;Thorpe, Mathew;Zheng, Bang;Chalmers, James D.;Ho, Ling-Pei;Horsley, Alex;Marks, Michael;Poinasamy, Krisnah;Raman, Betty;Harrison, Ewen M.;Wain, Louise, V;Brightling, Christopher E.
通讯作者：
Brightling, Christopher E.
DOI：
10.1016/s2213-2600(21)00383-0
发表时间：
2021-11
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Evans RA;McAuley H;Harrison EM;Shikotra A;Singapuri A;Sereno M;Elneima O;Docherty AB;Lone NI;Leavy OC;Daines L;Baillie JK;Brown JS;Chalder T;De Soyza A;Diar Bakerly N;Easom N;Geddes JR;Greening NJ;Hart N;Heaney LG;Heller S;Howard L;Hurst JR;Jacob J;Jenkins RG;Jolley C;Kerr S;Kon OM;Lewis K;Lord JM;McCann GP;Neubauer S;Openshaw PJM;Parekh D;Pfeffer P;Rahman NM;Raman B;Richardson M;Rowland M;Semple MG;Shah AM;Singh SJ;Sheikh A;Thomas D;Toshner M;Chalmers JD;Ho LP;Horsley A;Marks M;Poinasamy K;Wain LV;Brightling CE;PHOSP-COVID Collaborative Group
通讯作者：
PHOSP-COVID Collaborative Group
DOI：
10.1136/bmj.h5000
发表时间：
2015-09-29
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Dalal HM;Doherty P;Taylor RS
通讯作者：
Taylor RS
影响因子：
120.7
作者：
Puthucheary, Zudin A.;Rawal, Jaikitry;Montgomery, Hugh E.
通讯作者：
Montgomery, Hugh E.
影响因子：
2.9
作者：
通讯作者：
--